Skip to main content

Advertisement

Table 2 The correlation between SII and clinicopathologic characteristics in training and validation cohorts

From: Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer

Variables Training (N = 197) Validation (N = 222)
SII ≤ 440 % SII > 440 % P SII ≤ 440 % SII > 440 % P
Age (years)
 ≤ 60 39 42.9 56 52.8 0.198 41 46.1 64 48.1 0.785
 > 60 52 57.1 50 47.2   48 53.9 69 51.9  
Sex
 Male 55 60.4 67 63.2 0.769 62 69.7 85 63.9 0.389
 Female 36 39.6 39 36.8   27 30.3 48 36.1  
Location
 Head 34 37.4 53 50 0.085 38 42.7 52 39.1 0.676
 Body/tail 57 62.6 53 50   51 57.3 81 60.9  
Metastasis
 No 26 28.6 15 14.2 0.014 19 21.3 23 17.3 0.487
 Yes 65 71.4 91 85.8   70 78.7 110 82.7  
CA19-9 (U/mL)
 ≤ 37 22 50.0 22 50.0 0.609 22 42.3 30 57.7 0.748
 > 37 69 45.1 84 54.9   67 39.4 103 60.6  
TBIL (μmol/L)
 ≤ 17 80 87.9 82 77.4 0.062 77 86.5 107 80.5 0.278
 > 17 11 12.1 24 22.6   12 13.5 26 19.5  
ALB (g/L)
 ≤ 35 2 2.2 11 10.4 0.023 5 5.6 8 6.0 1.000
 > 35 89 97.8 95 89.6   84 94.4 125 94.0  
ALP (U/L)
 ≤ 125 70 76.9 69 65.1 0.085 71 79.8 86 64.7 0.016
 > 125 21 23.1 37 34.9   18 20.2 47 35.3  
ALT (U/L)
 ≤ 35 69 75.8 79 74.5 0.870 72 80.9 100 75.2 0.332
 > 35 22 24.2 27 25.5   17 19.1 33 24.8  
AST (U/L)
 ≤ 40 76 83.5 89 84.0 1.000 80 89.9 106 79.7 0.062
 > 40 15 16.5 17 16.0   9 10.1 27 20.3  
  1. CA carbohydrate antigen, TBIL total bilirubin, ALB albumin, ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate transaminase